TY - JOUR
T1 - An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs)
AU - Facchinetti, Fabio
AU - Cavalli, Pietro
AU - Copp, Andrew J
AU - D'Anna, Rosario
AU - Kandaraki, Eleni
AU - Greene, Nicholas D E
AU - Unfer, Vittorio
AU - Experts Group on Inositol in Basic and Clinical Research
AU - Appetecchia, Marialuisa
PY - 2020/12
Y1 - 2020/12
N2 - INTRODUCTION: Obstetric history and maternal body composition and lifestyle may be associated with serious complications both for the mother, such as gestational diabetes mellitus (GDM), and for the fetus, including congenital malformations such as neural tube defects (NTDs).AREAS COVERED: In view of the recent knowledge, changes in nutritional and physical activity habits ameliorate glycemic control during pregnancy and in turn improve maternal and neonatal health outcomes. Recently, a series of small clinical and experimental studies indicated that supplemenation with inositols, a family of insulin sensitizers, was associated with beneficial impact for both GDM and NTDs.EXPERT OPINION: Herein, we discuss the most significant scientific evidence supporting myo-inositol administration as a prophylaxis for the above-mentioned conditions.
AB - INTRODUCTION: Obstetric history and maternal body composition and lifestyle may be associated with serious complications both for the mother, such as gestational diabetes mellitus (GDM), and for the fetus, including congenital malformations such as neural tube defects (NTDs).AREAS COVERED: In view of the recent knowledge, changes in nutritional and physical activity habits ameliorate glycemic control during pregnancy and in turn improve maternal and neonatal health outcomes. Recently, a series of small clinical and experimental studies indicated that supplemenation with inositols, a family of insulin sensitizers, was associated with beneficial impact for both GDM and NTDs.EXPERT OPINION: Herein, we discuss the most significant scientific evidence supporting myo-inositol administration as a prophylaxis for the above-mentioned conditions.
U2 - 10.1080/17425255.2020.1828344
DO - 10.1080/17425255.2020.1828344
M3 - Article
C2 - 32966143
VL - 16
SP - 1187
EP - 1198
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
IS - 12
ER -